Catalyst Dossier · compiled by CeliA 🧫

Astellas Pharma (ALPMY)

Healthcare · market cap $24.1B · as of 2026-06-25

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-31 (est.)

Phase 2

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Non-US-listed company. Financial statements and forensic scores here come from US SEC filings (10-K/10-Q), which foreign issuers don’t file — those sections may be blank. The catalyst calendar, pipeline, approval odds, price context and (where covered) analyst targets still apply.

Astellas Pharma (ALPMY) is a Japanese multinational pharmaceutical company with 13,643 employees and a market cap of approximately $24.1B. The company operates a broad pipeline spanning transplantation, oncology, infectious disease, pain, and CNS indications, with OPT-80 in Phase 3 for Clostridioides difficile infection as the designated lead asset. Key near-term catalysts include Phase 3 and Phase 2 data readouts estimated through year-end 2026.

The catalyst path

2026-08-31 (est.)Phase 2 · nab-paclitaxelimp 7/10
2026-12-31 (est.)Phase 2 · leucovorinimp 7/10

Pipeline

Asset	Phase	Indication
OPT-80	Phase 3	Clostridium Difficile
Setidegrasib	Phase 3	Pancreatic Cancer
daclizumab	Phase 3	Kidney Transplantation
ASP1650	Phase 2	Incurable Platinum Refractory Germ Cell Tumors
YM177	Phase 3	Post Operative Pain
micafungin (Mycamine)	Phase 3	Fungemia
Erlotinib	Phase 2	NSCLC
quetiapine extended release (XR)	Phase 2	Major Depressive Disorder
VESIcare®	Phase 3	Urinary Bladder, Overactive
YM872 (zonampanel), t-PA (alteplase)	Phase 2	Acute Ischemic Stroke
CZP	Phase 3	Rheumatoid Arthritis
ASP4070	Phase 2	Rhinitis, Allergic, Seasonal
ASP4901	Phase 2	Benign Prostate Hyperplasia
Tacrolimus Inhalation Aerosol	Phase 2	Asthma
ASP2998	Phase 2	Locally Advanced or Metastatic Malignant Solid Tumors
Liposomal Amphotericin B	Phase 3	Candidiasis
YM529 / ONO-5920	Phase 3	Osteoporosis
Ramosetron	Phase 3	Vomiting
ASP5541	Phase 2	Prostate Cancer
Advagraf	Phase 3	Heart Transplantation

Price & technical context

3-month

+20.3%

6-month

+42.4%

12-month

+39.5%

52-wk range

$8.86–$13.65

vs 50-day MA

+12.4%

vs 200-day MA

+26.9%

Realized vol

23.8%

Max drawdown

-29.9%

Daily closes through 2025-12-23. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for ALPMY (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.